Please use this identifier to cite or link to this item:
|Title:||Sleep disruption in tetraplegia: a randomised, double-blind, placebo-controlled crossover trial of 3 mg melatonin.|
|Authors:||Spong, J;Kennedy, G A;Tseng, J;Brown, Douglas J;Armstrong, S M;Berlowitz, David J|
|Affiliation:||Institute for Breathing and Sleep, Austin Hospital, Melbourne, Victoria, Australia.|
1] Institute for Breathing and Sleep, Austin Hospital, Melbourne, Victoria, Australia  Psychology Department, College of Arts, Victoria University, Melbourne, Victoria, Australia  The Bronowski Institute of Behavioural Neuroscience, Kyneton, Victoria, Australia.
Department of Emergency Medicine, The Northern Hospital, Melbourne, Victoria, Australia.
Spinal Research Institute, Austin Health, Melbourne, Victoria, Australia.
1] The Bronowski Institute of Behavioural Neuroscience, Kyneton, Victoria, Australia  Epworth Sleep Centre, Melbourne, Victoria, Australia.
1] Institute for Breathing and Sleep, Austin Hospital, Melbourne, Victoria, Australia  Spinal Research Institute, Austin Health, Melbourne, Victoria, Australia  Department of Medicine, Austin Health and Northern Health, University of Melbourne, Melbourne, Victoria, Australia.
|Citation:||Spinal Cord 2014; 52(8): 629-34|
|Abstract:||Randomised, double-blind, placebo-controlled crossover trial of melatonin supplementation to people with complete tetraplegia.To investigate the effect that 3 mg melatonin supplementation has on objective and subjective sleep, quality of life and mood of people living with complete tetraplegia.Austin Hospital Sleep Laboratory and participants' homes, Melbourne, Victoria, Australia.Two week run-in followed by 3 week nightly administration of 3 mg melatonin or placebo, 2-week washout and further 3 week administration of the opposite treatment. Four testing sessions were conducted; the last nights of the run-in, treatment and washout periods. Testing sessions involved recording full polysomnography, completing a questionnaire battery and collecting urine and blood samples. The questionnaires assessed mood, sleep symptoms and health-related quality of life, and the urine and plasma samples assayed 6-sulphatoxymelatonin (aMT6s) and melatonin levels, respectively. A sleep diary was completed throughout the study.Eight participants (mean (s.d.): age 49.5 years (16), postinjury 16.9 years (7.1)) were recruited in which seven concluded the protocol. Endogenous-circulating melatonin was significantly higher (P < or = 0.01) following melatonin (urine: 152.94 μg h(-1) (74.51), plasma: 43,554.57 pM (33,527.11)) than placebo (urine: 0.86 μg h(-1) (0.40), plasma: 152.06 pM (190.55)). Subjective sleep improved significantly following melatonin specifically for duration of sleep per night and psychological wellbeing. Objective sleep showed a significant increase in light sleep with melatonin, with all other sleep parameters being unchanged.These results suggest that increasing melatonin in people with complete tetraplegia is beneficial, especially for subjective sleep. Investigation of the pharmacokinetics of melatonin metabolism in this population is warranted.This project is proudly supported by the Transport Accident Commission.|
|Internal ID Number:||24891007|
Melatonin.analogs & derivatives.blood.therapeutic use.urine
Quality of Life
Sleep Disorders.blood.drug therapy.etiology.urine
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.